Trial Profile
A Proof of Concept Study to Determine the Efficacy of Entresto™ in HFpEF Based on Circulating Neprilysin Levels: The Circulating NEP and NEP Inhibition (CNEPi) Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Feb 2022
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Biomarker; Proof of concept; Therapeutic Use
- Acronyms CNEPi
- 21 Apr 2021 Status changed from recruiting to completed.
- 05 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Mar 2021.
- 05 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Mar 2021.